X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
multiple sclerosis (22) 22
humans (21) 21
index medicus (20) 20
alemtuzumab (16) 16
clinical neurology (16) 16
male (16) 16
female (15) 15
adult (13) 13
neurosciences (12) 12
neurology (11) 11
middle aged (8) 8
adolescent (7) 7
care and treatment (7) 7
clinical trials (7) 7
drug therapy (7) 7
multiple sclerosis, relapsing-remitting - drug therapy (7) 7
patients (7) 7
young adult (7) 7
antibodies, monoclonal, humanized (6) 6
antibodies, monoclonal, humanized - therapeutic use (6) 6
diagnosis (6) 6
interferon (6) 6
treatment outcome (6) 6
disability (5) 5
monoclonal antibodies (5) 5
surgery (5) 5
antibodies, neoplasm - adverse effects (4) 4
autoimmune diseases (4) 4
autoimmunity (4) 4
campath-1h (4) 4
cohort studies (4) 4
disease (4) 4
double-blind (4) 4
immunologic factors - therapeutic use (4) 4
immunotherapy (4) 4
lymphocyte depletion (4) 4
medical research (4) 4
medicine & public health (4) 4
medicine, general & internal (4) 4
multiple sclerosis - drug therapy (4) 4
placebo-controlled trial (4) 4
psychiatry (4) 4
research (4) 4
abridged index medicus (3) 3
antibodies, monoclonal - adverse effects (3) 3
antibodies, monoclonal, humanized - adverse effects (3) 3
antibodies, neoplasm - therapeutic use (3) 3
antibody (3) 3
biological response modifiers (3) 3
biomedicine (3) 3
clinical medicine (3) 3
controlled phase-3 trial (3) 3
depletion (3) 3
disease progression (3) 3
disease-modifying therapy (3) 3
graves-disease (3) 3
immunology (3) 3
interferon beta (3) 3
internal medicine (3) 3
medicine (3) 3
monoclonal-antibody treatment (3) 3
multicenter (3) 3
multiple sclerosis - immunology (3) 3
neuroradiology (3) 3
prevalence (3) 3
receptors, n-methyl-d-aspartate - immunology (3) 3
risk factors (3) 3
studies (3) 3
t cells (3) 3
therapy (3) 3
thrombocytopenia (3) 3
thyroid (3) 3
time factors (3) 3
adjuvants, immunologic - adverse effects (2) 2
anti-glomerular basement membrane disease (2) 2
antibodies, monoclonal - administration & dosage (2) 2
antibodies, monoclonal - pharmacology (2) 2
antibodies, monoclonal - therapeutic use (2) 2
antibodies, monoclonal, humanized - administration & dosage (2) 2
antibodies, neoplasm - administration & dosage (2) 2
antibodies, neoplasm - pharmacology (2) 2
article (2) 2
autoimmune-diseases (2) 2
causes of (2) 2
comparative analysis (2) 2
disability evaluation (2) 2
dosage and administration (2) 2
encephalitis (2) 2
glatiramer acetate (2) 2
homeostasis (2) 2
immunoglobulins (2) 2
immunosuppressive agents (2) 2
immunosuppressive agents - administration & dosage (2) 2
immunosuppressive agents - adverse effects (2) 2
infection (2) 2
infections (2) 2
infusions, intravenous (2) 2
interferon beta-1a (2) 2
interferon-beta - therapeutic use (2) 2
licenses (2) 2
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 11/2012, Volume 380, Issue 9856, pp. 1829 - 1839
Journal Article
Journal Article
Lancet Neurology, The, ISSN 1474-4422, 2017, Volume 16, Issue 4, pp. 271 - 281
Journal Article
Journal of Clinical Immunology, ISSN 0271-9142, 1/2010, Volume 30, Issue 1, pp. 99 - 105
Treatment with alemtuzumab is highly effective in relapsing–remitting multiple sclerosis; however, 30% of patients develop autoimmunity. Alemtuzumab... 
reconstitution | Medical Microbiology | T1 B cell: transitional type I B cell | Biomedicine | Immunology | autoimmunity | BAFF: B-cell activating factor | Internal Medicine | Infectious Diseases | B cells | Autoimmunity | Reconstitution | RHEUMATOID-ARTHRITIS | SYSTEMIC-LUPUS-ERYTHEMATOSUS | REGENERATION | SJOGRENS-SYNDROME | DEPLETION | ANTIBODY | PERIPHERAL-BLOOD | IMMUNOLOGY | OVEREXPRESSION | RECOVERY | APRIL | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Immunologic Memory - drug effects | Antibodies, Monoclonal, Humanized | T-Lymphocytes - metabolism | T-Lymphocytes - drug effects | Adult | Female | B-Lymphocytes - pathology | T-Lymphocytes - pathology | B-Lymphocytes - metabolism | Multiple Sclerosis, Relapsing-Remitting - pathology | Cell Survival - drug effects | B-Cell Activating Factor - biosynthesis | Multiple Sclerosis, Relapsing-Remitting - immunology | Multiple Sclerosis, Relapsing-Remitting - blood | Multiple Sclerosis, Relapsing-Remitting - drug therapy | Cells, Cultured | Immunophenotyping | Alemtuzumab | Antibodies, Neoplasm - administration & dosage | B-Lymphocytes - drug effects | B-Lymphocytes - immunology | Antibodies, Monoclonal - administration & dosage | B-Cell Activating Factor - genetics | Cell Differentiation - drug effects | Adolescent | T-Lymphocytes - immunology | B-Cell Activating Factor - blood | Antibodies, Neoplasm - adverse effects | Multiple sclerosis | Memory (Computers) | Drug therapy | T cells
Journal Article
ISSN 0028-3878, 2016
$\textbf{Objective:}$ To describe detailed MRI results from 2 head-to-head phase III trials, Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis... 
Journal Article
BMJ Open, ISSN 2044-6055, 09/2018, Volume 8, Issue 9, p. e025333
IntroductionObservational studies indicate a potentially causal role for interleukin 6 (IL-6), a proinflammatory cytokine, in pathogenesis of depression, but... 
clinical trials | C-REACTIVE PROTEIN | MEDICINE, GENERAL & INTERNAL | INTERFERON-ALPHA | METAANALYSIS | SYMPTOMS | MENDELIAN RANDOMIZATION | MAJOR DEPRESSION | INTERLEUKIN-6 | ASSOCIATION | CHILDHOOD | IL-6
Journal Article
Journal of Neurology, Neurosurgery & Psychiatry, ISSN 0022-3050, 03/2012, Volume 83, Issue 3, pp. 298 - 304
Journal Article